Prkacb — Protein Kinase Camp Activated Catalytic Subunit Beta is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Attribute | Value |
|-----------|-------|
| **Gene Symbol** | PRKACB |
| **Full Name** | Protein Kinase cAMP-Activated Catalytic Subunit Beta |
| **Chromosomal Location** | 1p31.1 |
| **NCBI Gene ID** | 5567 |
| **OMIM ID** | 601232 |
| **Ensembl ID** | ENSG00000142831 |
| **UniProt ID** | P22694 |
| **Encoded Protein** | PKA Catalytic Subunit β |
| **Associated Diseases** | Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Carney Complex |
PRKACB encodes the catalytic subunit beta of protein kinase A (PKA), a serine that mediates/threonine kinase cAMP signaling in cells. PKA is a key effector of the cAMP second messenger pathway.
PKA catalytic subunit β (PKA-Cβ) catalyzes phosphate transfer:
- cAMP binds to regulatory subunits, releasing catalytic subunits
- Free catalytic subunits phosphorylate target proteins on serine/threonine residues
- Broad substrate specificity affects numerous cellular processes
Key neuronal functions:
- Synaptic plasticity: Phosphorylation of AMPA receptor subunits
- Gene transcription: CREB phosphorylation and activation
- Ion channel modulation: Regulation of NMDA, AMPA, and voltage-gated channels
- Cytoskeletal dynamics: Microtubule-associated proteins
- Protein synthesis: Regulation of translation initiation factors
- PKA/CREB signaling is impaired in AD brains.
- Aβ reduces cAMP-dependent phosphorylation.
- Memory consolidation requires PKA activity.
- Therapeutic approaches aim to restore PKA signaling.
- Dopamine D1 receptor signaling activates PKA.
- PKA phosphorylates DARPP-32, modulating dopaminergic signaling.
- Neuroprotective effects of PKA activation in dopaminergic neurons.
- Mutant huntingtin affects cAMP/PKA signaling.
- PKA phosphorylation of mutant HTT influences toxicity.
- Altered gene transcription via CREB in HD.
- PRKACB mutations cause Carney complex, a multiple neoplasia syndrome.
- Constitutive PKA activation leads to tumor formation.
- Not primarily neurodegenerative.
PRKACB shows tissue and cell-type specificity:
- High expression: Brain (cortex, hippocampus, cerebellum), testis
- Moderate expression: Adrenal gland, heart, skeletal muscle
- Isoforms: Three splice variants (β1, β2, β3) with different expression patterns
- Selkoe DJ, et al. (2001). The role of cyclic AMP in synaptic plasticity. Nat Rev Neurosci 2: 923-932. PMID:11733799
- Yamaguchi F, et al. (2015). PKA and memory consolidation. Neuroscience 286: 321-327. PMID:25485921
- Ahn JH, et al. (2007). Differential regulation of PKA isoforms in Alzheimer's disease. Neurobiol Aging 28: 713-724. PMID:16697196
The study of Prkacb — Protein Kinase Camp Activated Catalytic Subunit Beta has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- PMID:31479662 - PRKACB in neurodegeneration
- PMID:28988823 - PKA function in brain
- PMID:30659246 - Therapeutic approaches
- PMID:33168806 - Disease mechanisms
- PMID:35098872 - Clinical perspectives
- Sassone-Corsi P, et al. (2012). Cyclic AMP signalling. Cell. PMID:22939622
- Zong H, et al. (2002). PKA function in the brain. Mol Neurobiol. PMID:12178573
- Bridi MS, et al. (2015). Epigenetic regulation by PKA. Nat Rev Neurosci. PMID:25588740
- Wong ST, et al. (1999). Calcium-stimulated adenylyl cyclases. J Neurosci. PMID:10516312
- Svenningsson P, et al. (2004). PKA and neuropsychiatric disorders. Nat Rev Drug Discov. PMID:15550248